nach oben

Journal of NeuroVirology

Erschienen in:

01.04.2014 | Review

Complement and HIV-I infection/HIV-associated neurocognitive disorders

verfasst von: Fengming Liu, Shen Dai, Jennifer Gordon, Xuebin Qin

Erschienen in: Journal of NeuroVirology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The various neurological complications associated with HIV-1 infection, specifically HIV-associated neurocognitive disorders (HAND) persist as a major public health burden worldwide. Despite the widespread use of anti-retroviral therapy, the prevalence of HAND is significantly high. HAND results from the direct effects of an HIV-1 infection as well as secondary effects of HIV-1-induced immune reaction and inflammatory response. Complement, a critical mediator of innate and acquired immunity, plays important roles in defeating many viral infections by the formation of a lytic pore or indirectly by opsonization and recruitment of phagocytes. While the role of complement in the pathogenesis of HIV-1 infection and HAND has been previously recognized for over 15 years, it has been largely underestimated thus far. Complement can be activated through HIV-1 envelope proteins, mannose-binding lectins (MBL), and anti-HIV-1 antibodies. Complement not only fights against HIV-1 infection but also enhances HIV-1 infection. In addition, HIV-1 can hijack complement regulators such as CD59 and CD55 and can utilize these regulators and factor H to escape from complement attack. Normally, complement levels in brain are much lower than plasma levels and there is no or little complement deposition in brain cells. Interestingly, local production and deposition of complement are dramatically increased in HIV-1-infected brain, indicating that complement may contribute to the pathogenesis of HAND. Here, we review the current understanding of the role of complement in HIV-1 infection and HAND, as well as potential therapeutic approaches targeting the complement system for the treatment and eradications of HIV-1 infection.

Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A (2004) Development of the antibody response in acute HIV-1 infection. AIDS (London, England) 18:371–381

Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P et al (2005) Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79:2823–2830PubMedCentralPubMed

Abe K, Miyazaki M, Koji T, Furusu A, Ozono Y, Harada T, Sakai H, Nakane PK, Kohno S (1998) Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 54:120–130PubMed

Acosta J, Qin X, Halperin J (2004) Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10:203–211PubMed

Amet T, Ghabril M, Chalasani N, Byrd D, Hu N., Grantham A., Liu Z., Qin X., He JJ,Yu Q (2011). CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (Baltimore, Md.)

Bajtay Z, Speth C, Erdei A, Dierich MP (2004) Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 173:4775–4778PubMed

Beck EJ, Santas XM, Delay PR (2008) Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS (London, England) 22(Suppl 1):S75–S85

Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O, Lu XS, Pillot J (1995) Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172:691–697PubMed

Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD, Moore JP (1997) Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 71:2799–2809PubMedCentralPubMed

Borrow P, Shattock RJ, Vyakarnam A, Group, E.W (2010) Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 7:84PubMedCentralPubMed

Breitner S, Storkel S, Reichel W, Loos M (1995) Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum 38:492–498PubMed

Brodbeck WG, Mold C, Atkinson JP, Medof ME (2000) Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol 165:3999–4006PubMed

Bruder C, Hagleitner M, Darlington G, Mohsenipour I, Wurzner R, Hollmuller I, Stoiber H, Lass-Florl C, Dierich MP, Speth C (2004) HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol 40:949–961PubMed

Chatterjee A, Rathore A, Yamamoto N, Dhole TN (2011) Mannose-binding lectin (+54) exon-1 gene polymorphism influence human immunodeficiency virus-1 susceptibility in North Indians. Tissue Antigens 77:18–22PubMed

Chong YH, Lee MJ (2000) Expression of complement inhibitor protein CD59 in human neuronal and glial cell lines treated with HIV-1 gp41 peptides. J Neurovirol 6:51–60PubMed

Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J (2008) The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Investig 118:1244–1254PubMedCentralPubMed

Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB (1976) Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 144:970–984PubMed

Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP et al (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6:2833–2840PubMed

Datta PK, Rappaport J (2006) HIV and complement: hijacking an immune defense. Biomed Pharmacother 60:561–568PubMed

Davitz MA, Low MG, Nussenzweig V (1986) Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 163:1150–1161PubMed

De Rosa SD, McElrath MJ (2008) T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 3:375–379PubMed

Dierich MP, Stoiber H, Clivio A (1996) A "complementary" AIDS vaccine. Nat Med 2:153–155PubMed

Dzwonek A, Novelli V, Bajaj-Elliott M, Turner M, Clapson M, Klein N (2006) Mannose-binding lectin in susceptibility and progression of HIV-1 infection in children. Antivir Ther 11:499–505PubMed

Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP (1991) Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174:1417–1424PubMed

Eikelenboom P, Hack CE, Rozemuller JM, Stam FC (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Mol Pathol 56:259–262

Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA (1989) A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 169:185–196PubMed

Fisicaro N1, Aminian A, Hinchliffe SJ, Morgan BP, Pearse MJ, D’Apice AJ, Cowan PJ (2000) The pig analogue of CD59 protects transgenic mouse hearts from injury by human complement. Transplantation 70(6):963–968

Gasque P, Fontaine M, Morgan BP (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 154:4726–4733PubMed

Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:1389–1393PubMed

Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X (2011) rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 17:6702–6711PubMedCentralPubMed

Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, Masliah E, Commins DL, Brandt D, Grant I et al (2012) The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 7:e46178PubMedCentralPubMed

Giddings KS, Zhao J, Sims PJ, Tweten RK (2004) Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat Struct Mol Biol 11:1173–1178PubMed

Girard MP, Osmanov SK, Kieny MP (2006) A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24:4062–4081PubMed

Gregersen JP, Mehdi S, Baur A, Hilfenhaus J (1990) Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J Med Virol 30:287–293PubMed

Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ (1991) Induction of NF-kappa B during monocyte differentiation is associated with activation of HIV-gene expression. Res Virol 142:233–238PubMed

Guo RF, Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23:821–852PubMed

Haas PJ, van Strijp J (2007) Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res 37:161–175PubMed

Hart ML, Saifuddin M, Spear GT (2003) Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J Gen Virol 84:353–360PubMed

Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC (1993) Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS (London, England) 7:1307–1313

Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP (2001) Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98:442–449PubMed

Hu W, Ferris SP, Tweten RK, Wu G, Radaeva S, Gao B, Bronson RT, Halperin JA, Qin X (2008) Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 14:98–103PubMed

Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X (2010) A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 184:359–368PubMed

Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA et al (2011) Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71(6):2298–2307PubMedCentralPubMed

Huber M, Trkola A (2007) Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 262:5–25PubMed

Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3:e441PubMedCentralPubMed

Humbert M, Dietrich U (2006) The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51–59PubMed

Israels J, Scherpbier HJ, Frakking FN, van de Wetering MD, Kremer LC, Kuijpers TW (2012) Mannose-binding lectin and the risk of HIV transmission and disease progression in children: a systematic review. Pediatr Infect Dis J 31:1272–1278PubMed

Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ (2000) Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101:116–121PubMed

June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT (1991) Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS (London, England) 5:269–274

Kacani L, Banki Z, Zwirner J, Schennach H, Bajtay Z, Erdei A, Stoiber H, Dierich MP (2001) C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 166:3410–3415PubMed

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC et al (2013) Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Translat Med 5:185ra–163

Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776–788PubMed

Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antiviral Med 19:137–142

Letvin NL (2005) Progress toward an HIV vaccine. Annu Rev Med 56:213–223PubMed

Li H, Fu WP, Hong ZH (2013) Replication study in Chinese Han population and meta-analysis supports association between the MBL2 gene polymorphism and HIV-1 infection. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 20:163–170

Lin RC, Herman J, Henry L, Daniels GL (1988) A family showing inheritance of the Inab phenotype. Transfusion 28:427–429PubMed

Lu S (2008) Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 4:449–452PubMed

Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, Hansen JE (1995) Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 69:2393–2400PubMedCentralPubMed

Mangano A, Rocco C, Marino SM, Mecikovsky D, Genre F, Aulicino P, Bologna R, Sen L (2008) Detrimental effects of mannose-binding lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS progression. J Infect Dis 198:694–700PubMed

Martinez-Pinna R, Madrigal-Matute J, Tarin C, Burillo E, Esteban-Salan M, Pastor-Vargas C, Lindholt JS, Lopez JA, Calvo E, de Ceniga MV et al (2013) Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms. Arteriosclerosis Thromb Vasc Biol 33:2013–2020

Mayer MM (1984) Complement. Historical perspectives and some current issues. Complement (Basel Switzerland) 1:2–26

Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML (1987) Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A 84:2007–2011PubMedCentralPubMed

Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR (1994) Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82–92PubMed

Morgan BP (1999) Regulation of the complement membrane attack pathway. Crit Rev Immunol 19:173–198PubMed

Morgan BP, Gasque P (1997) Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 107:1–7PubMedCentralPubMed

Morris L (2002) Neutralizing antibody responses to HIV-1 infection. IUBMB Life 53:197–199PubMed

Mosser DM, Brittingham A (1997) Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology 115(Suppl):S9–S23PubMed

Nevo Y, Ben-Zeev B, Tabib A, Straussberg R, Anikster Y, Shorer Z, Fattal-Valevski A, Ta-Shma A, Aharoni S, Rabie M et al (2013) CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121:129–135PubMed

Nicholson-Weller A, Spicer DB, Austen KF (1985) Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 312:1091–1097PubMed

Ozkaya Sahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Mansson F, Norrgren H, Aaby P, Fenyo EM et al (2013) Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent. J Virol 87:273–281PubMedCentralPubMed

Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24:739–769PubMed

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 183:749–758PubMed

Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, Ragnaud JM, Bernard N, Fleury HJ (1996) Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 11:438–447PubMed

Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M (1994) Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Investig 93:2505–2513PubMedCentralPubMed

Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T (1992) Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retrovir 8:553–558PubMed

Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582–587PubMed

Prohaszka Z, Hidvegi T, Ujhelyi E, Stoiber H, Dierich MP, Susal C, Fust G (1995) Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85:184–189PubMedCentralPubMed

Prohaszka Z, Nemes J, Hidvegi T, Toth FD, Kerekes K, Erdei A, Szabo J, Ujhelyi E, Thielens N, Dierich MP et al (1997) Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS (London, England) 11:949–958

Pruenster M, Wilflingseder D, Banki Z, Ammann CG, Muellauer B, Meyer M, Speth C, Dierich MP, Stoiber H (2005) C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 35:2691–2698PubMed

Qin X, Gao B (2006) The complement system in liver diseases. Cell Mol Immunol 3:333–340PubMed

Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA (2003) Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 18:217–227PubMed

Qin X, Hu W, Song W, Grubissich L, Hu X, Wu G, Ferris S, Dobarro M, Halperin JA (2009) Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol 84:65–70PubMed

Reboul J, Schuller E, Pialoux G, Rey MA, Lebon P, Allinquant B, Brun-Vezinet F (1989) Immunoglobulins and complement components in 37 patients infected by HIV-1 virus: comparison of general (systemic) and intrathecal immunity. J Neurol Sci 89:243–252PubMed

Rees-Roberts D, Mullen LM, Gounaris K, Selkirk ME (2010) Inactivation of the complement anaphylatoxin C5a by secreted products of parasitic nematodes. Int J Parasitol 40:527–532PubMedCentralPubMed

Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, Liew YW, Tanner MJ (1991) Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 78:3291–3297PubMed

Reisinger EC, Vogetseder W, Berzow D, Kofler D, Bitterlich G, Lehr HA, Wachter H, Dierich MP (1990) Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS (London, England) 4:961–965

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220PubMed

Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144–4149PubMedCentralPubMed

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ (2009) The challenge of finding a cure for HIV infection. Science 323:1304–1307PubMed

Robinson HL (2007) HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82:686–693PubMed

Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Melendez LM, Ciborowski P (2007) Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 6:4189–4199PubMed

Rus H, Cudrici C, Niculescu F (2005) C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med 37:97–104PubMed

Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT (1995) Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CE59 in complement resistance of cell derived and primary isolates of HIV-1. J Exp Med 182:501–509PubMed

Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT (1997) Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78:1907–1911PubMed

Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT (2000) Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 81:949–955PubMed

Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA (1986) Activated terminal complement in cerebrospinal fluid in Guillain–Barre syndrome and multiple sclerosis. J Immunol 136:4456–4459PubMed

Sanders ME, Alexander EL, Koski CL, Frank MM, Joiner KA (1987) Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus. J Immunol 138:2095–2099PubMed

Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H (1995) Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Investig 96:1520–1526PubMedCentralPubMed

Sheng A, Lan J, Wu H, Lu J, Wang Y, Chu Q, Jia Z, Song M, Liu L, Wang W (2010) A clinical case–control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. Int J Immunogenet 37:445–454PubMed

Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD et al (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277–280PubMed

Singh KK, Lieser A, Ruan PK, Fenton T, Spector SA (2008) An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol 122:173–180, 180 e171-172PubMedCentralPubMed

Singh KK, Nathamu S, Adame A, Alire TU, Dumaop W, Gouaux B, Moore DJ, Masliah E, H.I.V.N.R.C.G. (2011) Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehav HIV Med 3:41–52PubMedCentralPubMed

Spear GT, Sullivan BL, Takefman DM, Landay AL, Lint TF (1991) Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 73:377–382PubMedCentralPubMed

Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S (1993) Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 67:53–59PubMedCentralPubMed

Speth C, Stockl G, Mohsenipour I, Wurzner R, Stoiber H, Lass-Florl C, Dierich MP (2001) Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol 75:2604–2615PubMedCentralPubMed

Speth C, Dierich MP, Gasque P (2002a) Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 38:669–679PubMed

Speth C, Schabetsberger T, Mohsenipour I, Stockl G, Wurzner R, Stoiber H, Lass-Florl C, Dierich MP (2002b) Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 76:3179–3188PubMedCentralPubMed

Speth C, Stoiber H, Dierich MP (2003) Complement in different stages of HIV infection and pathogenesis. Int Arch Allergy Immunol 130:247–257PubMed

Speth C, Williams K, Hagleitner M, Westmoreland S, Rambach G, Mohsenipour I, Schmitz J, Wurzner R, Lass-Florl C, Stoiber H et al (2004) Complement synthesis and activation in the brain of SIV-infected monkeys. J Neuroimmunol 151:45–54PubMed

Speth C, Dierich MP, Sopper S (2005) HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol 42:213–228PubMed

Spudich S, Gonzalez-Scarano F (2012) HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2:a007120PubMedCentralPubMed

Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP (1996) Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183:307–310PubMed

Stoiber H, Clivio A, Dierich MP (1997) Role of complement in HIV infection. Annu Rev Immunol 15:649–674PubMed

Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP (2001) The supportive role of complement in HIV pathogenesis. Immunol Rev 180:168–176PubMed

Stoiber H, Speth C, Dierich MP (2003) Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21(Suppl 2):S77–S82PubMed

Stoiber H, Banki Z, Wilflingseder D, Dierich MP (2008a) Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 26:3046–3054PubMed

Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, Dierich MP (2008b) Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 26(Suppl 8):I79–I85PubMed

Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S (1989) Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem (Tokyo) 106:555–557

Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC (1999) Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A 96:628–633PubMedCentralPubMed

Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G (1994) Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028–6034PubMed

Szabo J, Prohaszka Z, Toth FD, Gyuris A, Segesdi J, Banhegyi D, Ujhelyi E, Minarovits J, Fust G (1999) Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. AIDS (London, England) 13:1841–1849

Tan Y, Liu L, Luo P, Wang A, Jia T, Shen X, Wang M, Zhang S (2009) Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol 47:632–638PubMed

Telen MJ, Green AM (1989) The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 74:437–441PubMed

Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD (1995) Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 155:4861–4867PubMed

Tweten RK (2005) Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 73:6199–6209PubMedCentralPubMed

Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320:760–764PubMed

Welsh RM Jr, Cooper NR, Jensen FC, Oldstone MB (1975) Human serum lyses RNA tumour viruses. Nature 257:612–614PubMed

Welsh RM Jr, Jensen FC, Cooper NR, Oldstone MB (1976) Inactivation of lysis of oncornaviruses by human serum. Virology 74:432–440PubMed

Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA et al (2009) Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circulat Res 104:550–558PubMed

Wu G, Chen T, Shahsafaei A, Hu W, Bronson RT, Shi GP, Halperin JA, Aktas H, Qin X (2010) Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 121:1338–1346PubMedCentralPubMed

Xu Y, Zhang C, Jia L, Wen C, Liu H, Wang Y, Sun Y, Huang L, Zhou Y, Song H (2009) A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement. Virol J 6:123PubMedCentralPubMed

Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N et al (1990) Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323:1184–1189PubMed

Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT (2004) Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retrovir 20:327–335PubMed

Yu Q, Yu R, Qin X (2010) The good and evil of complement activation in HIV-1 infection. Cell Mole Immunol 7:334–340

Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D (1995) Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A 92:12426–12430PubMedCentralPubMed

Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13:954–966PubMed

Zhou HF, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, Song WC, Wu X, Thompson RW, Schwaeble WJ, Atkinson JP et al (2012) Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci U S A 109:E415–E422PubMedCentralPubMed

Titel: Complement and HIV-I infection/HIV-associated neurocognitive disorders
verfasst von: Fengming Liu
Shen Dai
Jennifer Gordon
Xuebin Qin
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Journal of NeuroVirology / Ausgabe 2/2014
Print ISSN: 1355-0284
Elektronische ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-014-0243-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Immune surveillance and response to JC virus infection and PML

The neuroimmune response to West Nile virus

Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology

Effect of morphine and SIV on dendritic cell trafficking into the central nervous system of rhesus macaques

Theiler’s murine encephalomyelitis virus as an experimental model system to study the mechanism of blood–brain barrier disruption